K V Pharmaceutical Co. Class A (NYSE:KV-A)
Develops advanced drug delivery technologies which enhance the effectiveness of new therapeutic agents, existing pharmaceutical products and prescription nutritional products.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
MajorBob04
(76.26)
Submitted: 2/7/2012 7:16:04 AM :
Start Price:
$3.01
KV-A Score:
-46.32
Here we go again. . .
Recs
withoutlimits
(82.45)
Submitted: 1/10/2012 9:31:57 PM :
Start Price:
$1.41
KV-A Score:
+10.52
Maybe.............
Recs
siri22
(< 20)
Submitted: 11/9/2011 1:53:03 AM :
Start Price:
$1.65
KV-A Score:
-9.40
Lttle chinese mix>
Recs
acts20
(85.36)
Submitted: 11/4/2011 3:57:11 PM :
Start Price:
$1.01
KV-A Score:
+53.32
Very important new drug could save millions on premies..should be a standard for high risk women
Recs
Cochuso
(< 20)
Submitted: 10/27/2011 1:42:59 PM :
Start Price:
$1.31
KV-A Score:
+18.95
Why this stock is not presente in Google Finance
Recs
Recs
kkconway
(99.12)
Submitted: 6/1/2011 11:18:43 AM :
Start Price:
$3.44
KV-A Score:
-53.50
The Parliament of Whores and Pond-Scum Procurers in the Capitol Building (...and don't even get me started on the Democrats!) can't screw up everything. Look for a recovery when the Congress finds bigger fish to burn with their wanton magnifying glass.
Recs
Sagemanx
(42.46)
Submitted: 5/30/2011 1:17:45 AM :
Start Price:
$3.32
KV-A Score:
-50.90
Looks like a bounce from here...
Recs
robertshrestha
(63.72)
Submitted: 4/29/2011 9:19:01 AM :
Start Price:
$4.07
KV-A Score:
+58.88
Too much uncertainty right now, still coming under heavy fire, significant price drop on Makena will hurt margins going forward, stock still up quite a bit since FDA approval (even with recent plunge). Too risky for my blood.
Recs
greenbreen
(31.47)
Submitted: 4/26/2011 12:53:52 PM :
Start Price:
$4.00
KV-A Score:
+59.14
Why get back in? The pipeline? Personally, the local obstetrics community's reaction here was/is that Makena was a pathetic attempt to manipulate the FDA, doctors, insurances and patients and I could see this leading to a backlash and blacklisting led by physicians, who in the US, are gatekeepers to pharmaceuticals. Unless KV demonstrates some value over the compounded product the pharmacist has been mixing on the bench for forever AND does some serious physician PR work (despite their altruism, doctors tend to hold grudges against those that arm twist them and profit unethically from their patients that were being served well ), I think the company may have bet the farm and lost big here.
Recs
numby98
(< 20)
Submitted: 4/21/2011 11:56:59 AM :
Start Price:
$4.10
KV-A Score:
-60.95
No doubt ,KV has the exclusive rights to Makena which has FDA approval and Doctors will turn to Makena as their sole recomendation for women who have lost pre-term babies, and are now pregnant...
Recs
EnigmaDude
(98.87)
Submitted: 4/14/2011 1:01:03 PM :
Start Price:
$3.96
KV-A Score:
-61.36
getting oversold enough to tiptoe back in.
Recs
lancer009
(< 20)
Submitted: 4/6/2011 2:59:48 AM :
Start Price:
$4.65
KV-A Score:
-65.52
its just matter of time
Recs
ChrisGraley
(99.70)
Submitted: 4/5/2011 11:37:14 PM :
Start Price:
$4.65
KV-A Score:
-65.52
Alright, I''ve rode this up and then red thumbed it and rode it down. It's priced to be a good choice for the long run again.
Recs
samarthyaa
(< 20)
Submitted: 4/5/2011 9:17:13 PM :
Start Price:
$4.65
KV-A Score:
-65.52
I strongly believe that KV is taking right steps toward the pricing. Makena is a very important drug and will be having a huge user base in coming months. Makena deserves a primium pricing over compound pharmacies drug, and I guess no body has a doubt against it considering the safety and underneath cose involved plus a responsible company behind it. To me, it seems like some of the articles/disucssion is unnecessary and very negatively approached.
I am long on KV.
Recs
randomvariable
(98.70)
Submitted: 4/4/2011 2:21:11 PM :
Start Price:
$5.14
KV-A Score:
-69.44
Rode it up on the FDA approval, getting back in after the lower-than-hoped-for price news. I think it will still move up.
Recs
teigman
(< 20)
Submitted: 3/9/2011 7:22:45 PM :
Start Price:
$12.82
KV-A Score:
-89.93
Makena has amazing potential- On the basis of the New England Jounal of Medicine Article 2003 the drug truly does benefit in preterm labor. Demand is going to be hard to fill. OBs use this drug on a regular basis compounded from pharmacies. It is going to make it a lot easier to dispense to patients. In the end we will help prevent much of the sequela from preterm labor if taken in time. It is truly a breakthrough...
Recs
tahoejack
(< 20)
Submitted: 3/7/2011 7:13:24 PM :
Start Price:
$10.38
KV-A Score:
-86.46
New drug with hot chart a little competition
Recs
ablengata
(72.62)
Submitted: 2/25/2011 8:25:59 PM :
Start Price:
$8.00
KV-A Score:
-80.91
This one is going to fly. With their recently approved Makena, a medication labelled to treat pre-term birth, this company is definitely going places. They currently hold FDA approval for the only medication currently available that is specifically labelled to prevent pre-term births. The market for this medication is huge, and KV-A won't have any competitors for quite some time. The next year will be very interesting as KV begins marketing and selling Makena this March 2011.
In addition to all of this, KV-A also has other projects and medications in their pipeline to strengthen the fundamentals even more. This one is a winner, for sure. The next year will probably be turbulent, but a strong upward trend will ultimately prevail.
Recs
doctorsynthesis
(< 20)
Submitted: 2/25/2011 11:36:30 AM :
Start Price:
$8.07
KV-A Score:
-81.92
These guys have a blockbuster on their hands (Makena)....why? ppl have to realize two things: Makena is a huge profit margin drug ($1500 per injection) and it will be covered by all healthcare plans (see below).
While the number of premature births (and thus the market for Makena) may not be as large as for typical blockbuster drugs, the cost to the healthcare system from premature births is disproportionately high. This is what allows Makena to get away with such high margins since $1500 per injection to prevent a premature birth is still way cheaper than the costs of long-term care for premature babies in hospitals. This is money in the bank for K V.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 59 : 1 2 3 Next »